Aim-To present the clinical, dermatological, and histological features of a patient with generalised xanthomatosis, familial apolipoprotein (apo) E deficiency, and unusual type III hyperlipoproteinaemia (HLP). Methods-The underlying molecular defect was disclosed using molecular biological techniques. The unusual xanthomas were histologically analysed and the morphology of the abnormal lipoprotein particles examined using electron microscopy. Results-A 10 base pair deletion in exon 4 of the proband's apo £ gene (base pairs 4037-4046 coding for amino acids 209-212 ofthe mature protein) was identified. This is predictive for a reading frameshift encoding a premature stop (TGA) in codon 229. The mutation is responsible for delayed catabolism of atherogenic lipoprotein remnants, lipid storage in monocyte/macrophages, and phenotypic expression of xanthomatosis early in life. Conclusions-Familial apo E deficiency is a rare genetic disease which offers the unique opportunity to study the impact of apo E on lipoprotein metabolism and development of atherosclerosis in humans. (_ Clin Pathol 1996;49:985-989) 
only about 2% of these genetically predisposed individuals develop type III HLP at some stage of their lives. Hence the prevalence of this lipoprotein disorder is estimated to be around 1 in 5000 in the general population. Therefore, apo E2 homozygosity is a necessary but not sufficient condition for the development of the disorder. This suggests that type III HLP is a multifactorial disease-that is, additional factors, either genetic or environmental, are required for its phenotypic expression.7 A severe form of type III HLP is caused by complete or relative lack of functionally active apo E (familial apo E deficiency). This, however, is a rare genetic condition, and so far only four independent cases have been reported.8'-2 In only two of the analysed patients have the underlying molecular defects been disclosed.'2 13 Recently, we identified a further subject with familial apo E deficiency and xanthomatosis.'4 The molecular defect was a 10 base pair deletion in exon 4 of the proband's apo £ gene. We now describe in detail the clinical, dermatological, and histological features of this person. Characterisation of such cases is mandatory, as apo E deficiency offers the unique opportunity to study and assess the impact of apo E on lipoprotein metabolism and development of atherosclerosis in human subjects.
Methods
Venous blood samples were obtained in the morning after a fast of at least 12 hours. Serum was extracted for analysis of total cholesterol, triglycerides, and high density lipoprotein (HDL) cholesterol, which were measured using enzymatic kits from Boehringer Mannheim, Mannheim, Germany.
Genomic DNA was isolated from nucleated blood cells contained in 10 ml of EDTA blood according to the method of Miller et al. '5 The 3' part of exon 4 of the apo £ gene'6 from the patient and control subjects was amplified using the polymerase chain reaction (PCR) in an automated DNA thermocycler exactly as described elsewhere.'4 Amplified DNA products were analysed for size on a 2% agarose gel. PCR products were subcloned via "TA cloning into pCR II-vector" (Invitrogen, Heidelberg, Germany). Several clones were used for DNA sequence analysis, which was carried out using T7 DNA polymerase (Pharmacia, Freiburg, Germany).
Apo E phenotypes were determined using one dimensional isoelectric focusing (IEF) of plasma, as described before.'7 Lipoproteins were separated by sequential ultracentrifugation into VLDL (d < 1.006 g/ml), IDL (d, 1.006-1.019 g/ml), LDL (d, 1.019-1.063 g/ml), and HDL (d, 1.063-1.21 g/ml), as described before. 18 Negative staining for electron microscopy was performed as described.'9 In short, a drop of each lipoprotein specimen (20 gl) was care- Figure 3 Orange-yellowish discolourations of the palmar creases (xanthoma striata palmaris) in apo E deficiency.
fully pipetted on a copper grid covered with a thin film of polyvinyl formaldehyde. After a short drying period (60 seconds) phosphotungstic acid (4% in 0.4% saccharose solution, pH 7.0) was used for negative staining of the lipoprotein particles for 15 minutes. The grids were dried and examined with an electron microscope (Zeiss TEM 109 T, Oberhochen, Germany).
Results
While screening hyperlipidaemic subjects for apo E phenotypes, a patient with apo E deficiency was identified. The proband (BG) was a slightly obese (weight 78 (fig 4) but did not totally normalise the dyslipidaemia in the patient. However, this is the first report of efficient fenofibrate treatment in familial apo E deficiency.
In conclusion, apo E deficiency results in severe type III HLP and generalised atypical xanthomatosis. The underlying metabolic defect is an accumulation of atherogenic lipoprotein remnants, probably as a result of reduced affinity of these (apo E depleted) particles to lipoprotein receptors. The disturbances of lipoprotein metabolism created by the lack of a functionally active apo E seem to be even more pronounced than those caused by structural variants of apo E. Hence apo E deficiency is a rare but unique human model system that permits the study of the effects of apo E on lipoprotein metabolism and the subsequent development of atherosclerosis.
Electron microscopy was kindly done by Professor H-J Grone, Medizinisches Zentrum fur Pathologie, Marburg, Germany. 
